Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FlyteHealth vs Medsol RX

FlyteHealth
Graded #364

Lower grade

vs+2.3999999999999986
Medsol RX
Graded #306

Higher grade

The verdict

Medsol RX takes it — 61/100 to 58.6/100.

Medsol RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medsol RX is a GLP-1 weight-loss telehealth program offering compounded semaglutide (from $209/mo) and tirzepatide, prescribed by board-certified clinicians via OpenLoop and shipped nationwide.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationMedsol RX +24
40
64
Clinical oversightFlyteHealth +4
83
79
Labs & monitoringFlyteHealth +20
73
53
FulfillmentMedsol RX +21
62
83
Contract termsFlyteHealth +14
55
41
FlyteHealth · left barMedsol RX · right bar

The numbers

MetricFlyteHealthMedsol RX
WeighScore58.6/10061/100
GradeCC
Scorecard rank#364#306
SemaglutideNot disclosed$209/mo (compounded)
TirzepatideNot disclosed$250/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
FlyteHealth

Graded #364 · C

Strengths

  • Care led by board-certified obesity-medicine physicians
  • Multidisciplinary team with NPs, dietitians, and care coordinators
  • Published outcomes of about 13 to 16 percent weight loss over 12 months
  • High GLP-1 medication adherence (around 86 percent in reported data)
  • Comprehensive cardiometabolic care beyond GLP-1 alone

Where it loses points

  • Distributed primarily via employers, payers, and health plans, not direct cash-pay
  • Access is largely gated behind employer or plan sponsorship
  • GLP-1 is prescribed only when appropriate, not guaranteed
  • Self-pay pricing is not publicly listed (contact required)
  • Less suited to consumers wanting fast direct-to-door GLP-1
Medsol RX

Graded #306 · C

Strengths

  • Compounded semaglutide from $209/mo (12-mo plan) and tirzepatide from ~$250/mo; HSA/FSA eligible with Klarna financing
  • Every plan bundles the medication, a dedicated care coach, custom treatment plan, medical oversight, and free shipping
  • Board-certified clinicians via OpenLoop; same-day approvals; ships nationwide
  • Month-to-month option ($199 first month) with no long-term commitment, plus microdosing and wellness add-ons

Where it loses points

  • Doesn't name its compounding pharmacy (generic 'certified U.S. pharmacies')
  • No legal entity name published on the site
  • Tirzepatide pricing is given as a range ($250-$1,400/mo), not a fixed rate
  • Compounded GLP-1s are not FDA-approved (the site discloses this)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard